Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ENDOTARGET

Financiado

Cerrado

Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and nove...

Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic targets for Arthritis Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very high economic burden. In this project, we will explore the role of chronic systemic inflammat... ver más

31/12/2026

HUS

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

HUSYHTYMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-15

HORIZON-HLTH-2022-STAYHLTH-02-01: Personalised blueprint of chronic i... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

HUS

1.76M€ | Lider

EUROPEAN BIOMEDICAL RESEARCH...

698.75K€ | Participante

FUNDACION INSTITUTO DE INVES...

657.02K€ | Participante

TU WIEN

546.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ENDOTARGET Systemic Endotoxemia as the driver of chronic inflammation -... 7M€ Cerrado

PID2021-122391OB-I00 MICROBIOTA INTESTINAL Y RESPUESTA INMUNE: DESENTRAÑANDO NUEV... 254K€ Cerrado

MaRiA Microbiota and Resolvins in Arthritis 195K€ Cerrado

WePredict Microbiota and immune responses at weaning predict the susce... 2M€ Cerrado

COHABIT Consequences of helminth bacterial interactions 1M€ Cerrado

MIRA Characterizing Microbe specific Immune Responses in the path... 174K€ Cerrado

Duración del proyecto: 49 meses Fecha Inicio: 2022-11-15
Fecha Fin: 2026-12-31

Líder del proyecto

HUSYHTYMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very high economic burden. In this project, we will explore the role of chronic systemic inflammation caused by intestinal microbiota derived immunologically active compounds, as a driver in the transition from health to disease, with a special focus on three RDs; osteoarthritis (OA), rheumatoid arthritis (RA), and spondylarthritis (SpA). We aim to explore the relationship between gut microbiota, intestinal permeability, and endotoxemia. We aim to understand their role as drivers of disease onset and disease activity in RA, SpA and OA, as well as targets of preventive and therapeutic approaches. We will study the events leading from health to disease onset by i) taking advantage of geographically diverse large cohorts of people with available blood and faeces samples, ii) search for novel risk biomarkers for RA, SpA, and OA by using high-throughput OMICS-based analyses iii) conducting targeted clinical studies, iv) performing in vitro mechanistic studies to explore the gut-joint axis using tissue explant cultures and organ-on-chip models v) conducting interventional proof of concept studies of diet, faecal transplantation and a gut permeability decreasing drug in RA and SpA patients, vi) exploring in vitro new potential drugs or nutraceuticals to cope with endotoxemia effects on target tissues. By combining all these results, machine learning and AI-informed rheumatic disease prediction tool will be developed for clinicians to help them identify patients with increased risk of developing the target diseases. It will thus assist in the choice of personalized blueprint intervention to reduce the risk of these diseases and disease activity in RA and SpA and to slow down the progression of OA.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores